Schlagwort: prostate cancer
Cause of metastasis in prostate cancer discovered
6. April 2022
Prostate cancers remain localized in the majority of cases, giving affected individuals a good chance of survival. However, about 20% of patients develop incurable metastatic prostate cancer, resulting in approximately 5,000 deaths each year in Austria alone. Medical research has not yet adequately explained why metastases occur in some people and not in others. A research team has now discovered specific changes in a protein that drive the growth and spread of prostate cancer.
Cause of metastasis in prostate cancer discovered
6. April 2022
Prostate cancers remain localized in the majority of cases, giving affected individuals a good chance of survival. However, about 20% of patients develop incurable metastatic prostate cancer, resulting in approximately 5,000 deaths each year in Austria alone. Medical research has not yet adequately explained why metastases occur in some people and not in others. A research team has now discovered specific changes in a protein that drive the growth and spread of prostate cancer.
New risk algorithm would improve screening for prostate cancer
9. März 2022
Researchers developed an algorithm estimating a person’s risk of developing prostate cancer based on age and the levels of two prostate cancer markers, PSA and hK2 (human kalliknein peptidase). They found that, by setting a risk threshold above which men are counted as ’screen positive‘, the approach would reduce the number of false positives by three quarters compared to a standard PSA test, while catching the same proportion of cancers.
Virtual patient ‘surrogates’ can personalize cancer treatments
17. Februar 2022
Scientists have developed mathematical models that act as patient ’surrogates‘ for evaluating potential prostate cancer treatments.
Advanced prostate cancer antibody drug shows success in pet dogs
8. Februar 2022
Mice are typically used as models in advanced prostate cancer research, but the profound differences between them and humans has long bedeviled the translation of findings from the animal to success in people. Dogs however are the only other animal that suffers from a significant incidence of prostate cancer, and researchers are finding them much more enlightening subjects in identification of drugs that show promise for human patients.
New blood test combined with image-based prostate cancer screening reduces harms and costs
29. Januar 2022
The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study.
Genetic clues link lipoprotein A to prostate cancer risk
28. Januar 2022
A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A.
Assessing Progression Risk in Cancer
13. Januar 2022
A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according to a new study. The team also identified ERV expression signatures that may be useful for identifying prostate cancer patients at greatest risk of progression regardless of ancestry, which may also extend to progression in other cancers.
Portable prostate cancer test may help reach underserved men
7. Januar 2022
A highly portable and rapid prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer and particularly those with limited access to health care, such as African American men.
The prostate cancer cell that got away
17. November 2021
Researchers have pioneered a new method to track the progression of prostate cancer in mice, from its birth to its spread into other tissues. This approach allows researchers to study the origins of prostate cancer in a more realistic context than traditional methods allow.
New strategy against treatment-resistant prostate cancer identified
6. November 2021
A new study has identified an RNA molecule that suppresses prostate tumors. The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow. According to the new research — conducted in mice implanted with human prostate tumor samples — restoring this so-called long noncoding RNA could be a new strategy to treat prostate cancer that has developed resistance to hormonal therapies.
Prostate cancer urine test identifies good prognosis patients
4. November 2021
Researchers have shown that a prostate cancer urine test can identify men at ‚intermediate risk‘ who can safely avoid immediate treatment and benefit from ‚active surveillance‘ instead. Previously, the team’s Prostate Urine Risk (PUR) test could identify men with high and low risk cancers. But thanks to some fine-tuning, it can now help men with intermediate-risk disease – for whom treatment options had been less clear.
Targeted prostate cancer screening could benefit men with inherited cancer syndrome
23. Oktober 2021
Men who inherit an increased risk of cancer through ‚Lynch syndrome‘ could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe. Annual PSA tests were eight times more likely to spot cancer in men with genetic hallmarks of Lynch syndrome than those without. Experts say evidence could be incorporated into a targeted screening program in future.
‘Gut bugs’ can drive prostate cancer growth and treatment resistance
9. Oktober 2021
Common gut bacteria can become ‚hormone factories‘ – fuelling prostate cancer and making it resistant to treatment, a new study shows. Scientists revealed how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy — by providing an alternative source of growth-promoting androgens, or male hormones. The findings, once further validated in the clinic, could provide new opportunities for the treatment of prostate cancer through manipulation of the microbiome.
A global assessment of cancer genomic alterations in epigenetic mechanisms
5. März 2015
Muhammad A Shah, Emily L Denton, Cheryl H Arrowsmith, Mathieu Lupien and Matthieu Schapira
Abstract
Background
The notion that epigenetic mechanisms may be central to cancer initiation and progression is supported by recent next-generation sequencing efforts revealing that genes involved in chromatin-mediated signaling are recurrently mutated in cancer patients.
Results
Here, we analyze mutational and transcriptional profiles from TCGA and the ICGC across a collection 441 chromatin factors and histones. Chromatin factors essential for rapid replication are frequently overexpressed, and those that maintain genome stability frequently mutated. We identify novel mutation hotspots such as K36M in histone H3.1, and uncover a general trend in which transcriptional profiles and somatic mutations in tumor samples favor increased transcriptionally repressive histone methylation, and defective chromatin remodeling.
Conclusions
This unbiased approach confirms previously published data, uncovers novel cancer-associated aberrations targeting epigenetic mechanisms, and justifies continued monitoring of chromatin-related alterations as a class, as more cancer types and distinct cancer stages are represented in cancer genomics data repositories.
Continue reading „A global assessment of cancer genomic alterations in epigenetic mechanisms“ →